<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Cannon, Christopher P.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">DEFINE: CETP Inhibition with Anacetrapib Significantly Raises HDL Cholesterol and Further Lowers LDL</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses results from the Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib [DEFINE; NCT00685776] trial, which showed that anacetrapib safely and substantially lowered LDL-C and raised HDL-C levels in patients with coronary heart disease.</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>